Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

Latest Prostate Cancer News and Research

New approach harnesses disease-causing proteins to combat cancer

Over many decades now, traditional drug discovery methods have steadily improved at keeping diseases at bay and cancer in remission. And for the most part, it's worked well.

26 Feb 2021

Renalytix AI and University of Utah announce partnership to improve kidney health

Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah, one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.

25 Feb 2021

High-throughput genetic analysis can help dissect the mechanism of disease inheritance

Many genetic variants have been found to have a linkage with genetic diseases, but the understanding of their functional roles in causing diseases are still limited.

24 Feb 2021

Polygenic hazard score improves prediction of prostate cancer risk in multi-ethnic populations

Building upon previous research, an international team led by scientists at University of California San Diego School of Medicine, has validated a more inclusive and comprehensive genetic tool for predicting age of onset of aggressive prostate cancer, a disease that killed more than 33,000 American men in 2020.

23 Feb 2021

Psychosocial factors may contribute to dropout of patients from peritoneal dialysis

A retrospective study conducted by LSU Health New Orleans reports that contrary to previous research, most patients who drop out of peritoneal dialysis may do so for psychosocial reasons.

20 Feb 2021

Targeting MAPK4 enzyme may be a potential new strategy to combat prostate cancer

The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease.

20 Feb 2021

Researchers track how Osmium reacts in a single cancer cell

Osmium is a rare precious metal that could be used to treat cancer with fewer side effects when compared to Platinum, currently used in nearly half of chemotherapies.

17 Feb 2021

Researchers identify molecular link between inflammatory signaling molecule and a main oncogene

A team of MedUni Vienna researchers led by Johannes A. Schmid at the Center for Physiology and Pharmacology, Institute of Vascular Biology and Thrombosis Research, has managed to identify a previously unknown molecular connection between an inflammatory signaling molecule and one of the main oncogenes.

17 Feb 2021

Mathematical model reveals how cell turnover determines the success of adaptive therapy

One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.

17 Feb 2021

New model predicts which patients will gain most from PSMA PET scan

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

16 Feb 2021

New urine test could avoid unnecessary prostate cancer biopsies

A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.

11 Feb 2021

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

11 Feb 2021

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin

Oncotarget recently published "Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment" which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019.

11 Feb 2021

Study reveals why Black men with prostate cancer have greater survival benefits from immunotherapy

Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment.

10 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

Researchers from Hong Kong Baptist University and the Faculty of Medicine at The Chinese University of Hong Kong have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer.

8 Feb 2021

Cancer patients less likely to receive life-saving therapy when suffering a heart attack

A major study of nearly 2 million heart attack patients has found that many who also had cancer were not offered a potentially lifesaving treatment, despite the fact it had major benefits.

4 Feb 2021

New process separates beneficial glucocorticoids from unwanted side-effects

A collaboration led by Scripps Research has developed a way to separate the beneficial anti-inflammatory properties of a group of steroids called glucocorticoids from some of their unwanted side-effects, through an optimization process they named "ligand class analysis."

3 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021